Principal Financial Group Inc. Has $5.66 Million Stock Position in Certara, Inc. (NASDAQ:CERT)

Principal Financial Group Inc. boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 531,445 shares of the company’s stock after buying an additional 15,739 shares during the period. Principal Financial Group Inc. owned about 0.33% of Certara worth $5,660,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its position in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. KBC Group NV boosted its stake in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the period. GAMMA Investing LLC boosted its stake in Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after purchasing an additional 6,868 shares during the period. Moloney Securities Asset Management LLC purchased a new position in Certara during the 4th quarter worth approximately $128,000. Finally, Summit Trail Advisors LLC acquired a new stake in Certara during the 4th quarter valued at $138,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Trading Down 0.3 %

Shares of NASDAQ CERT opened at $11.94 on Tuesday. The business has a 50 day simple moving average of $12.48 and a 200 day simple moving average of $11.63. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -59.70, a PEG ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Barclays raised their target price on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.